secwatch.observer — SEC 8-K summary
======================================

Issuer:     Editas Medicine, Inc. (EDIT)
CIK:        0001650664
Form:       8-K
Filed at:   2023-01-09T23:59:59+00:00
Accession:  0001558370-23-000130
Event type: leadership
Sentiment:  negative
Materiality: 0.50
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Editas CSO Mark Shearman to step down effective March 31, 2023
--------------------------------------------------------------

- Dr. Shearman departs as CSO and EVP; effective March 31, 2023.
- Separation agreement: 12 months base salary, COBRA, and 2022 bonus.
- Agreement includes standard non-disparagement and confidentiality clauses.
- No successor named; CEO Gilmore O'Neill signed the filing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1650664/000155837023000130/0001558370-23-000130-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1650664/000155837023000130/edit-20230107x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-000130

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer